- Home
- CRGY vs IMCR Comparison
CRGY vs IMCR Comparison
Compare CRGY & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGY
- IMCR
- Stock Information
- Founded
- CRGY 1986
- IMCR 2008
- Country
- CRGY United States
- IMCR United Kingdom
- Employees
- CRGY N/A
- IMCR N/A
- Industry
- CRGY Oil & Gas Production
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRGY Energy
- IMCR Health Care
- Exchange
- CRGY Nasdaq
- IMCR Nasdaq
- Market Cap
- CRGY 2.1B
- IMCR 1.5B
- IPO Year
- CRGY N/A
- IMCR 2021
- Fundamental
- Price
- CRGY $8.51
- IMCR $28.84
- Analyst Decision
- CRGY Buy
- IMCR Buy
- Analyst Count
- CRGY 11
- IMCR 11
- Target Price
- CRGY $17.33
- IMCR $59.11
- AVG Volume (30 Days)
- CRGY 4.1M
- IMCR 264.3K
- Earning Date
- CRGY 05-05-2025
- IMCR 05-07-2025
- Dividend Yield
- CRGY 5.74%
- IMCR N/A
- EPS Growth
- CRGY N/A
- IMCR N/A
- EPS
- CRGY N/A
- IMCR N/A
- Revenue
- CRGY $3,223,618,000.00
- IMCR $333,581,000.00
- Revenue This Year
- CRGY $29.75
- IMCR $20.26
- Revenue Next Year
- CRGY N/A
- IMCR $8.49
- P/E Ratio
- CRGY N/A
- IMCR N/A
- Revenue Growth
- CRGY 31.58
- IMCR 25.75
- 52 Week Low
- CRGY $6.83
- IMCR $23.15
- 52 Week High
- CRGY $16.94
- IMCR $62.22
- Technical
- Relative Strength Index (RSI)
- CRGY 45.29
- IMCR 53.17
- Support Level
- CRGY $7.71
- IMCR $27.88
- Resistance Level
- CRGY $8.75
- IMCR $31.38
- Average True Range (ATR)
- CRGY 0.33
- IMCR 1.47
- MACD
- CRGY 0.13
- IMCR 0.01
- Stochastic Oscillator
- CRGY 65.35
- IMCR 60.31
About CRGY Crescent Energy Company
Crescent Energy Co is an independent energy company with a portfolio of assets in key basins across the lower 48 states. The company maintains a diverse portfolio of assets in key basins across the United States, including the Eagle Ford, Rockies, Barnett, Permian, and Mid-Con. It seeks to deliver attractive risk-adjusted investment returns and predictable cash flows across cycles with a focus on operated oil and gas assets complemented by non-operated assets, mineral and royalty interests, and midstream infrastructure.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.